MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3

MBX has fleshed out plans to take in over $136 million from its IPO as the biotech looks to bring a potential challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3.